![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
German antibody maker valued at $1.6B in blank-check merger
The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell engagers and bispecific drugs for cancer.
The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell engagers and bispecific drugs for cancer.
